Kirby McInerney LLP is investigating potential claims against the Board
of Directors of Chelsea Therapeutics International, Ltd. ("Chelsea
Therapeutics" or the "Company") (NASDAQ: CHTP) concerning the proposed
acquisition of the Company by H. Lundbeck A/S ("Lundbeck"). Under the
terms of the definitive merger agreement, Chelsea Therapeutics
stockholders will receive $6.44 in cash and up to $1.50 in Contingent
Value Rights for each share of Chelsea Therapeutics owned, representing
a total potential consideration of up to $658 million.
The investigation concerns whether the Chelsea Therapeutics Board of
Directors violated its fiduciary duties by ageeing to the proposed
transaction and whether the proposed consideration adequately values
Chelsea Therapeutics' common stock.
If you are a Chelsea Therapeutics stockholder and wish to obtain
additional information, please contact J. Brandon Walker, Esq. by email
at email@example.com, by
telephone at (212) 699-1145 or (888) 529-4787, or by filling
out this contact form. There is no cost or obligation to you.
Kirby McInerney LLP is a New York-based law firm concentrating in
securities, shareholder, whistleblower, antitrust and consumer
litigation. For additional information, please go to www.kmllp.com.
[ Back To NFVZone's Homepage ]